Synaptogenix, Inc. (SNPX)
- Previous Close
2.2200 - Open
2.3225 - Bid --
- Ask --
- Day's Range
2.1600 - 2.3978 - 52 Week Range
1.8400 - 5.0500 - Volume
13,490 - Avg. Volume
8,206 - Market Cap (intraday)
3.002M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-10.9900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synaptogenix, Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. The company was incorporated in 2012 and is headquartered in New York, New York.
www.synaptogen.comRecent News: SNPX
View MorePerformance Overview: SNPX
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNPX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNPX
View MoreValuation Measures
Market Cap
3.00M
Enterprise Value
-13.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.43%
Return on Equity (ttm)
-78.91%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.56M
Diluted EPS (ttm)
-10.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
17.66M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7M